Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine
暂无分享,去创建一个
Xiansheng Huang | W. Dai | Yiqi Zhang | F. Luo | Jingmei Xiao | L. Shen | Wenqiang Zhu | Piaopiao Huang | Pingan Lian | Juanli Ran | Rong Li | Yang Yang | Yaqing Tang
[1] Yang Yang,et al. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[2] Y. Qian,et al. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition , 2021, Journal of lipid research.
[3] C. Correll,et al. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics , 2020, Drugs.
[4] Shelly C. Lu,et al. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. , 2020, Cell metabolism.
[5] I. Romenskaia,et al. High density lipoprotein promotes nascent apolipoprotein A-V secretion from mRNA transfected cells. , 2019, Biochemical and biophysical research communications.
[6] Shuiping Zhao,et al. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway. , 2016, Biochemical and biophysical research communications.
[7] J. Ou,et al. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials , 2016, Molecular Psychiatry.
[8] T. Forte,et al. Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism. , 2015, Current drug targets.
[9] D. Vancampfort,et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis , 2015, World psychiatry : official journal of the World Psychiatric Association.
[10] S. Baker,et al. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers , 2015, Pathology.
[11] Anette Varbo,et al. Triglycerides and cardiovascular disease , 2014, The Lancet.
[12] K. Wenner,et al. Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. , 2014, Atherosclerosis.
[13] Xinmin Yin,et al. Olanzapine Activates Hepatic Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic Dysregulation with Atypical Antipsychotic Drugs , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[14] Shuiping Zhao,et al. The role of apolipoprotein A5 in obesity and the metabolic syndrome , 2013, Biological reviews of the Cambridge Philosophical Society.
[15] M. A. Lasunción,et al. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro[S] , 2013, Journal of Lipid Research.
[16] Xuan Gao,et al. Influence of apolipoprotein A-V on hepatocyte lipid droplet formation. , 2012, Biochemical and biophysical research communications.
[17] T. Forte,et al. Apolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlement. , 2012, Biochimica et biophysica acta.
[18] Marc De Hert,et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.
[19] S. Leal,et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. , 2011, Atherosclerosis.
[20] G. Olivecrona,et al. Apolipoprotein A-V; a potent triglyceride reducer. , 2011, Atherosclerosis.
[21] Paul G Shekelle,et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. , 2011, JAMA.
[22] G. S. Shelness,et al. Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion[S] , 2011, Journal of Lipid Research.
[23] R. Stafford,et al. Increasing off‐label use of antipsychotic medications in the United States, 1995–2008 , 2011, Pharmacoepidemiology and drug safety.
[24] C. Correll,et al. Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients , 2010, Neuropsychopharmacology.
[25] J. Baik,et al. Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice. , 2010, Biochemical and biophysical research communications.
[26] E. Johansson,et al. Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole , 2010, International Journal of Obesity.
[27] R. Coccurello,et al. 30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice , 2009, Journal of clinical psychopharmacology.
[28] Barbara Napolitano,et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.
[29] Shuiping Zhao,et al. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up‐regulating peroxisome proliferator‐activated receptor‐α , 2009, British journal of pharmacology.
[30] T. Forte,et al. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice Published, JLR Papers in Press, December 3, 2007. , 2008, Journal of Lipid Research.
[31] Jing-ping Zhao,et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. , 2008, JAMA.
[32] P. Talmud. Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review. , 2007, Atherosclerosis.
[33] Yen-Hui Chen,et al. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. , 2007, Pharmacological research.
[34] H. Ploegh. A lipid-based model for the creation of an escape hatch from the endoplasmic reticulum , 2007, Nature.
[35] H. Yoshida,et al. Prediction of genetic risk for metabolic syndrome. , 2007, Atherosclerosis.
[36] Li‐jun Wu,et al. Association of human serum apolipoprotein A5 with lipid profiles affected by gender. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[37] D. Brasaemle,et al. Isolation of Lipid Droplets from Cells by Density Gradient Centrifugation , 2005, Current protocols in cell biology.
[38] K. V. van Dijk,et al. Apolipoprotein AV: low concentration, high impact. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[39] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[40] L. Pennacchio,et al. Apolipoprotein A-V Deficiency Results in Marked Hypertriglyceridemia Attributable to Decreased Lipolysis of Triglyceride-Rich Lipoproteins and Removal of Their Remnants , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[41] L. Pennacchio,et al. Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase* , 2005, Journal of Biological Chemistry.
[42] A. Cantafora,et al. Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[43] K. V. van Dijk,et al. ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis* , 2004, Journal of Biological Chemistry.
[44] L. Pennacchio,et al. Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[45] J. W. Gallagher,et al. Structure and Interfacial Properties of Human Apolipoprotein A-V* , 2003, Journal of Biological Chemistry.
[46] Len A Pennacchio,et al. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[47] P. Reitsma,et al. Apolipoprotein A-V , 2001, The Journal of Biological Chemistry.
[48] Jonathan C. Cohen,et al. An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.
[49] B. Trump,et al. Mouse liver cell culture , 1981, In Vitro.
[50] B. Trump,et al. Mouse liver cell culture , 1981, In Vitro.
[51] T. Grandin,et al. AVMA Guidelines for the Euthanasia of Animals: 2013 Edition , 2013 .
[52] D. Battle,et al. Diagnostic and Statistical Manual of Mental Disorders (DSM). , 2013, CoDAS.
[53] Robert G. Parton,et al. Opinion: Lipid droplets: a unified view of a dynamic organelle , 2006, Nature Reviews Molecular Cell Biology.
[54] Christiane,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.